Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.
This was a multi-arm phase 2 diabetes trial
A United States phase 2 trial randomly assigned 281 adults with type 2 diabetes across placebo, an active comparator and several retatrutide regimens. It was randomized, double-blind and double-dummy, with follow-up reported through 36 weeks and registration as NCT04867785.
The prespecified primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to week 24. Later glycaemic and body-weight outcomes were also reported, but the primary endpoint identifies the central hypothesis the trial was designed to test.
Evidence should become more specific as a claim becomes more consequential.
Comparator context changes the interpretation
The paper reported dose-group differences in HbA1c change at week 24 relative to placebo, as well as 36-week results and an active-comparator arm. It also reported that 237 participants completed the study and 222 completed study treatment, which is relevant when assessing how much follow-up data were available.
Gastrointestinal adverse events were commonly reported in the investigational groups. A complete reading retains these safety observations, the comparator and the trial population alongside efficacy results rather than presenting only one outcome.
- Link to the original source.
- Name the study design and population.
- Report the observed endpoint factually.
- Disclose important limitations.
- Never convert trial reporting into a product recommendation.
Phase 2 data remain protocol-specific
The participants had type 2 diabetes and defined eligibility criteria; results are not automatically transferable to other populations, timeframes or uses. The publication was funded by Eli Lilly, which is relevant disclosure context when appraising the evidence.
This literature record is educational only. It does not establish the identity, purity, safety, dose or expected performance of a non-trial material and provides no treatment recommendation.
Primary references
These sources were checked against the linked publisher, regulator or literature-index record on 21 July 2026.
- Rosenstock et al. Retatrutide for people with type 2 diabetes: randomized, double-blind, placebo- and active-controlled phase 2 trial. Lancet. 2023. PMID 37385280.
- ClinicalTrials.gov. NCT04867785: Retatrutide in participants with type 2 diabetes.
